These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36346929)

  • 1. Association Between Aromatase Inhibitors and Myocardial Infarction Morbidity in Women With Breast Cancer: A Meta-Analysis of Observational Studies.
    Sun JC; Sun ZF; He CJ; Zhai CL; Qian G
    Cancer Control; 2022; 29():10732748221132512. PubMed ID: 36346929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study.
    Kamaraju S; Shi Y; Smith E; Nattinger AB; Laud P; Neuner J
    Clin Cardiol; 2019 Jan; 42(1):93-100. PubMed ID: 30443921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials.
    Qian X; Li Z; Ruan G; Tu C; Ding W
    Breast Cancer Res Treat; 2020 Jan; 179(2):275-285. PubMed ID: 31606823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of cardiovascular disease in breast cancer patients receiving aromatase inhibitors vs. tamoxifen: A systematic review and meta-analysis.
    Yu Q; Xu Y; Yu E; Zheng Z
    J Clin Pharm Ther; 2022 May; 47(5):575-587. PubMed ID: 34984740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-reducing medications for primary breast cancer: a network meta-analysis.
    Mocellin S; Goodwin A; Pasquali S
    Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012191. PubMed ID: 31032883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.
    Khosrow-Khavar F; Filion KB; Bouganim N; Suissa S; Azoulay L
    Circulation; 2020 Feb; 141(7):549-559. PubMed ID: 32065766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson LJ; Dawson C; Lawrence DH; Bliss JM
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aromatase inhibitors and the incidence of Parkinson disease: A population-based cohort study.
    Khosrow-Khavar F; Azoulay L; Montastruc JL; Montastruc F; Renoux C
    Cancer; 2022 Jun; 128(12):2339-2347. PubMed ID: 35363379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiotoxicity of Use of Sequential Aromatase Inhibitors in Women With Breast Cancer.
    Khosrow-Khavar F; Bouganim N; Filion KB; Suissa S; Azoulay L
    Am J Epidemiol; 2020 Oct; 189(10):1086-1095. PubMed ID: 32338279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study.
    Sund M; Garcia-Argibay M; Garmo H; Ahlgren J; Wennstig AK; Fredriksson I; Lindman H; Valachis A
    Breast; 2021 Oct; 59():157-164. PubMed ID: 34265496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients.
    Ligibel JA; James O'Malley A; Fisher M; Daniel GW; Winer EP; Keating NL
    Breast Cancer Res Treat; 2012 Jan; 131(2):589-97. PubMed ID: 21881937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer.
    Abdel-Qadir H; Amir E; Fischer HD; Fu L; Austin PC; Harvey PJ; Rochon PA; Lee DS; Anderson GM
    Eur J Cancer; 2016 Nov; 68():11-21. PubMed ID: 27693889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials.
    Corona SP; Roviello G; Strina C; Milani M; Madaro S; Zanoni D; Allevi G; Aguggini S; Cappelletti MR; Francaviglia M; Azzini C; Cocconi A; Sirico M; Bortul M; Zanconati F; Giudici F; Rosellini P; Meani F; Pagani O; Generali D
    Breast; 2019 Aug; 46():19-24. PubMed ID: 31051411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.
    Robertson JFR; Paridaens RJ; Lichfield J; Bradbury I; Campbell C
    Eur J Cancer; 2021 Mar; 145():19-28. PubMed ID: 33418233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer.
    Gupta T; Purington N; Liu M; Han S; Sledge G; Schapira L; Kurian AW
    Breast Cancer Res Treat; 2022 Nov; 196(1):175-183. PubMed ID: 36030472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis.
    He Y; Zhang J; Shen G; Liu L; Zhao Q; Lu X; Yang H; Hong D
    BMC Pharmacol Toxicol; 2019 Oct; 20(1):62. PubMed ID: 31665091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Disease After Aromatase Inhibitor Use.
    Haque R; Shi J; Schottinger JE; Chung J; Avila C; Amundsen B; Xu X; Barac A; Chlebowski RT
    JAMA Oncol; 2016 Dec; 2(12):1590-1597. PubMed ID: 27100398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data.
    Choi SH; Kim KE; Park Y; Ju YW; Jung JG; Lee ES; Lee HB; Han W; Noh DY; Yoon HJ; Moon HG
    Breast; 2020 Dec; 54():25-30. PubMed ID: 32890789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
    Conte P; Frassoldati A
    Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.